The Clause 3.2 minimum information, the generic name rule, claims and comparisons, advertising to the public, and what UCPMP 2024 does not cover. Each page answers one question directly and names the provision it rests on.
The five items UCPMP 2024 Clause 3.2 requires where promotional material is meant to inform a prescribing decision, quoted from the Code.
What UCPMP 2024 Section 2 requires of claims and comparisons in Indian pharmaceutical promotion, quoted from the Code, including the two words the Code names directly.
Which instruments restrict advertising medicines to the general public in India: the Drugs and Cosmetics Rules 1945 bar on advertising Schedule H, H1 and X drugs without Central Government sanction, and the Drugs and Magic Remedies Act 1954 disease list that catches non-prescription products too.
Requirements commonly attributed to UCPMP 2024 that are not in it: the Rx symbol, statutory schedule warnings, font sizes and generic-name size parity.
General guidance for pharmaceutical marketing teams in India. Regulation and its interpretation change, and this page may not reflect the current position. It is not legal, regulatory or medical advice and it does not replace your own medical, legal and regulatory review. Please verify against the source text before relying on anything here. ImpactPlus Ventures LLP accepts no liability for decisions taken on the basis of this page.